ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$11.66
0.54 (4.86%)
▲
5d:
+6.0%
30d:
+12.98%
90d:
+38.81%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 19, 2026
3d
Smart Money Accumulation
ZVRA is down 7.8% this week, but smart money is accumulating calls. Top strike: $11 2026-06-18 with 12 OI. Call ratio: 100% View Scanner →
Strength: 8.9/10
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called ZVRA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 17.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 17.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.65
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.24
53.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $11.66, which is considered extended relative to its 30-day fair value range of $9.74 to $10.90. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.1) compared to its historical average (10.9). Remarkably, the market is currently pricing in an annual earnings decline of 17.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $10.01, while resistance sits at $12.06. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.00 (+97.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $10.01, while resistance sits at $12.06. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.00 (+97.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.74 -
$10.90
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range (+7.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 97.3% below Wall St target ($23.00)
Trading Range Analysis
30-Day Trading Range
$9.74 -
$10.90
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.01
Resistance Level
$12.06
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.09
Wall Street Target
$23.00
(+97.3%)
Revenue Growth (YoY)
77.5%
Profit Margin
101.6%
Valuation Discount vs History
-17.7% cheaper
PE vs Historical
6.1 vs 10.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.7%
(market-implied from PE analysis)
1-Year Target
$10.49
(-10%)
2-Year Target
$9.44
(-19%)
3-Year Target
$8.50
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→11)
$15.22
(+31%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 64.4%)
$142.45
(+1122%)
Base:
(SPY PE: 6.1, Growth: 64.4%)
$39.35
(+238%)
Bear:
(PE: 5.2, Growth: 64.4%)
$33.45
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 5.53 | Current EPS (TTM): $2.01
Bull Case
$11.65
(0%)
Analyst growth -4.7%, PE expands to 6.1
Base Case
$10.59
(-9%)
Market implied -4.7%, PE stable at 5.5
Bear Case
$7.56
(-35%)
Severe decline -20.0%, PE contracts to 4.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.1 to 10.9
Stabilization Target:
$20.87
(+79.0%)
PE Expansion Potential:
+79.0%
Share & Embed Analysis
Last updated: May 14, 2026 7:19 PM ET
Data refreshes hourly during market hours. Next update: 8:19 PM
Data refreshes hourly during market hours. Next update: 8:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 60 BUY |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 54 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$181 | 59 HOLD |
|
VYGR
Voyager Therapeutics Inc |
STRONG BUY
12 analysts |
$15 | 58 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
